By G HossainPosted on October 23, 2026Posted in Pharmaceutical & Bio Science, UncategorizedTagged bio science career, blogs, business career news, career tips, job blog, job news, RJF Pharmaceutical Jobs Gilead Sciences has picked up a new inflammatory disease program from China’s PepStar Therapeutics to pair with the Phase 2 inflammatory bowel disease asset emvistegrast. Gilead shops in IL-23, inking $1.3B upfront I&I deal with China’s PepStar Post navigation US explores China biotech restrictions, exempts licensing dealsRoche flags ‘final opportunity’ for Germany to reestablish as a reliable investment location
